The possible role of maintenance treatment for primary central nervous system lymphoma
- 1 September 2018
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 32 (5) , 378-386
Abstract
No abstract availableKeywords
This publication has 117 references indexed in Scilit:
- Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)Journal of Clinical Oncology, 2013
- Clonal evolution in cancerNature, 2012
- Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primatesCancer Chemotherapy and Pharmacology, 2011
- Cognitive functions in primary CNS lymphoma after single or combined modality regimensNeuro-Oncology, 2011
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood, 2011
- Phase I Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors: Pediatric Brain Tumor Consortium Study PBTC-018Journal of Clinical Oncology, 2011
- Review: Chemotherapy in newly diagnosed primary central nervous system lymphomaTherapeutic Advances in Medical Oncology, 2010
- High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphomaNeuro-Oncology, 2010
- Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 StudyJournal of Clinical Oncology, 2009
- Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphomaHaematologica, 2009